United States· US:59762-1350_25e74b16-cdf0-4959-be62-1745c4e4cf0a
Rifabutin
A rifabutin product containing rifabutin, registered in United States by Mylan Pharmaceuticals Inc.. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rifabutin is registered in 15 of 19 countries.
Countries holding a registration under ATC J04AB04 (rifabutin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Rifabutin · ATC J04AB04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rifabutin costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rifabutin · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$5.51
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RIFABUTIN
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- J04AB04
- ATC class
- Rifabutin
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 19, 2026
Packs & prices · 2
- ndc115976213501100 CAPSULE in 1 BOTTLE (59762-1350-1)
- ndc1159762-1350-1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
278 interactions on record for rifabutin.
Graded by severity as the source publishes them — 91 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifabutin · interactions on record
278 records
- 91 severe
- 146 moderate
- 8 minor
Most severe, free to view
- RolapitantA04AD14severe
- EliglustatA16AX10severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
33 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rifabutin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayAnsatipinSERB
- FinlandAnsatipinParanova Oy
- United KingdomMycobutin 150mg capsulesPfizer Ltd
- SpainANSATIPIN 150 MG CÁPSULAS DURASBinesa 2002 S.L.
- BelgiumMycobutin 150 mgPfizer
- IrelandMycobutin 150mg Hard CapsulesPfizer Healthcare Ireland Unlimited Company
- NetherlandsMycobutin, capsules 150 mgPfizer B.V.
- SwedenAnsatipin 150 mg Kapsel, hårdPfizer AB
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Mycobutin
- Belgium · Mycobutin
- Czechia · Mycobutin
- Germany · Mycobutin
- Spain · Ansatipin
- Finland · Ansatipin
- France · Ansatipine
- United Kingdom (Northern Ireland) · Mycobutin, Rifabutin Pfizer
- Ireland · Mycobutin
- Italy · Mycobutin
- Luxembourg · Mycobutin
- Netherlands · Mycobutin
- Portugal · Mycobutin
- Sweden · Ansatipin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f4eddee9-127e-404c-b32a-b74c4908c109 GET /v1/drugs/f4eddee9-127e-404c-b32a-b74c4908c109?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "150",
"substance": "RIFABUTIN",
"productndc": "59762-1350",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA050689",
"marketing_category": "NDA AUTHORIZED GENERIC"
}See everything about rifabutin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.